MedTrace Logo

Frailty and Cognitive Function in Parkinson's Disease.

NCT05388526 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-12-21

No results posted yet for this study

Summary

Introduction: Parkinson's disease (PD) is the association of tremor, rigidity, akinesia-bradykinesia and loss of postural reflexes. Non-motor symptoms such as cognitive impairment may also develop. Cognitive impairment can be highly variable in its progression, symptoms and severity and can begin from the onset of the disease to the most advanced stages. Frailty is a syndrome characterized by a decrease in physiological reserve that results in an individual's increased vulnerability, which can lead to a variety of adverse factors when exposed to stressors. PD and frailty are highly prevalent in older people and are associated with increased morbidity and mortality. The presence of frailty in patients with PD is poorly studied, as is the association between cognitive impairment and frailty in this patient profile.

Objective: Evaluate the relationship between frailty and cognitive impairment in patients with PD or secondary parkinsonism.

Study design: observational, descriptive, correlative and cross-sectional.

Study population: The subjects that will be part of this study will be men and women with a diagnosis of PD or secondary parkinsonism belonging to the Health Area V of the Health Service of the Principality of Asturias, Spain.

Conditions

  • Parkinson Disease

Interventions

OTHER

No intervention

There was no intervention to be administered, only collection of data through various tests and questionnaires.

Sponsors & Collaborators

  • University of Oviedo

    lead OTHER

Principal Investigators

  • MC Sousa-Fraguas · University of Oviedo

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-25
Primary Completion
2023-05-31
Completion
2023-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05388526 on ClinicalTrials.gov